Nanhua Bio Medicine Stock Current Valuation
| 000504 Stock | 10.07 0.09 0.89% |
Valuation analysis of Nanhua Bio Medicine helps investors to measure Nanhua Bio's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Nanhua Bio's Cash is projected to increase significantly based on the last few years of reporting. The current year's Other Cashflows From Investing Activities is expected to grow to about 1.6 M, whereas Total Cashflows From Investing Activities is projected to grow to (13.8 M). Fundamental drivers impacting Nanhua Bio's valuation include:
Price Book 13.3657 | Enterprise Value 3 B | Enterprise Value Ebitda -2.3 K | Price Sales 26.7046 | Enterprise Value Revenue 24.3674 |
Overvalued
Today
Please note that Nanhua Bio's price fluctuation is slightly risky at this time. Calculation of the real value of Nanhua Bio Medicine is based on 3 months time horizon. Increasing Nanhua Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Nanhua Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Nanhua Stock. However, Nanhua Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.07 | Real 7.82 | Hype 10.07 | Naive 9.92 |
The real value of Nanhua Stock, also known as its intrinsic value, is the underlying worth of Nanhua Bio Medicine Company, which is reflected in its stock price. It is based on Nanhua Bio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Nanhua Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Nanhua Bio Medicine helps investors to forecast how Nanhua stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nanhua Bio more accurately as focusing exclusively on Nanhua Bio's fundamentals will not take into account other important factors: Nanhua Bio Medicine Company Current Valuation Analysis
Nanhua Bio's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Nanhua Bio Current Valuation | 3.03 B |
Most of Nanhua Bio's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nanhua Bio Medicine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Nanhua Bio Medicine has a Current Valuation of 3.03 B. This is 89.44% lower than that of the Media sector and significantly higher than that of the Communication Services industry. The current valuation for all China stocks is 81.76% higher than that of the company.
Nanhua Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nanhua Bio's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nanhua Bio could also be used in its relative valuation, which is a method of valuing Nanhua Bio by comparing valuation metrics of similar companies.Nanhua Bio is currently under evaluation in current valuation category among its peers.
Nanhua Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.0455 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 3.03 B | ||||
| Shares Outstanding | 330.02 M | ||||
| Shares Owned By Insiders | 13.01 % | ||||
| Shares Owned By Institutions | 40.52 % | ||||
| Price To Book | 13.37 X | ||||
| Price To Sales | 26.70 X | ||||
| Revenue | 136.79 M | ||||
| Gross Profit | 127.36 M | ||||
| EBITDA | (38.19 M) | ||||
| Net Income | (28.17 M) | ||||
| Total Debt | 28.12 M | ||||
| Book Value Per Share | 0.75 X | ||||
| Cash Flow From Operations | 36.28 M | ||||
| Earnings Per Share | (0.12) X | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 3.32 B | ||||
| Total Asset | 771.38 M | ||||
| Retained Earnings | (531.1 M) | ||||
| Working Capital | 202.45 M | ||||
| Net Asset | 771.38 M |
About Nanhua Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nanhua Bio Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nanhua Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nanhua Bio Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Nanhua Stock
Nanhua Bio financial ratios help investors to determine whether Nanhua Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nanhua with respect to the benefits of owning Nanhua Bio security.